HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Cytokine in cancer chemotherapy--clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia].

Abstract
Clinical trials of IL-3, IL-11 and thrombopoietin (TPO) against chemotherapy-induced thrombocytopenia were reviewed. Many clinical trials of IL-3 were conducted, which increased the platelet nadir counts and improved the recovery from thrombocytopenia at a dose of 5 micrograms/kg/day for 7 to 14 days. Major side effects, fever and headache, were tolerable. The combination with G-CSF was also examined. IL-11 improved the platelet nadir counts and the recovery from thrombocytopenia at a dose of 50 micrograms/kg/day for 14 days. Adverse events of IL-11 were general fatigue and edema, which were mild. Phase I/II studies of TPO were conducted, which showed a marked increase of platelet counts and improvement in recovery from thrombocytopenia. A few patients experienced mild thrombo-embolism. Improved QOL and survival benefits in the evaluation of these cytokines must be demonstrated.
AuthorsS Kudoh, M Yamada
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 25 Issue 2 Pg. 171-6 (Jan 1998) ISSN: 0385-0684 [Print] JAPAN
PMID9474925 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Interleukin-11
  • Interleukin-3
  • Granulocyte Colony-Stimulating Factor
  • Thrombopoietin
  • Carboplatin
  • Paclitaxel
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Carboplatin (adverse effects)
  • Carcinoma, Non-Small-Cell Lung (blood, drug therapy)
  • Clinical Trials as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Administration Schedule
  • Granulocyte Colony-Stimulating Factor (administration & dosage)
  • Humans
  • Interleukin-11 (administration & dosage)
  • Interleukin-3 (administration & dosage)
  • Lung Neoplasms (blood, drug therapy)
  • Paclitaxel (adverse effects)
  • Platelet Count
  • Randomized Controlled Trials as Topic
  • Thrombocytopenia (chemically induced, therapy)
  • Thrombopoietin (administration & dosage)
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: